Ivosidenib

Ivosidenib (AG-120) is an orally active inhibitor of isocitrate dehydrogenase 1 mutant (mIDH1) enzyme, it exhibits profound d-2-hydroxyglutatrate (2-HG) lowering in vivo. Ivosidenib (AG-120) has the potential for AML therapy due to its acceptable safety profile and clinical activity[1].

Product Specifications

CAS Number

[1448347-49-6]

Product Name Alternative

AG-120

UNSPSC

12352005

Hazard Statement

H315, H317, H319, H335

Target

Isocitrate Dehydrogenase (IDH)

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

Cancer-programmed cell death

Field of Research

Cancer; Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/Ivosidenib.html

Concentration

10mM

Purity

99.89

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

ClC1=C([C@H](N(C2=CC(F)=CN=C2)C([C@H]3N(C4=NC=CC(C#N)=C4)C(CC3)=O)=O)C(NC5CC(F)(F)C5)=O)C=CC=C1

Molecular Formula

C28H22ClF3N6O3

Molecular Weight

582.96

Precautions

H315, H317, H319, H335

References & Citations

[1]Popovici-Muller J, et al. Discovery of AG-120 (Ivosidenib) : A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1Mutant Cancers. ACS Med Chem Lett. 2018 Jan 19;9 (4) :300-305.